These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 17611218)

  • 21. Heart of darkness: the downside of trastuzumab.
    Hayes DF; Picard MH
    J Clin Oncol; 2006 Sep; 24(25):4056-8. PubMed ID: 16908930
    [No Abstract]   [Full Text] [Related]  

  • 22. [Cardiotoxicity of trastuzumab of significance in the adjuvant treatment of breast cancer].
    Menke-van der Houven van Oordt CW; Fliervoet HJ; Mandigers CM; van Spronsen DJ
    Ned Tijdschr Geneeskd; 2008 Jan; 152(3):158-63. PubMed ID: 18271465
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation.
    Cardinale D; Colombo A; Torrisi R; Sandri MT; Civelli M; Salvatici M; Lamantia G; Colombo N; Cortinovis S; Dessanai MA; Nolè F; Veglia F; Cipolla CM
    J Clin Oncol; 2010 Sep; 28(25):3910-6. PubMed ID: 20679614
    [TBL] [Abstract][Full Text] [Related]  

  • 24. On the recovery of trastuzumab-related cardiac dysfunction.
    Gillham CM; Chalmers AC; Plowman PN
    Clin Oncol (R Coll Radiol); 2001; 13(2):146. PubMed ID: 11373881
    [No Abstract]   [Full Text] [Related]  

  • 25. The acute skin and heart toxicity of a concurrent association of trastuzumab and locoregional breast radiotherapy including internal mammary chain: a single-institution study.
    Caussa L; Kirova YM; Gault N; Pierga JY; Savignoni A; Campana F; Dendale R; Fourquet A; Bollet MA
    Eur J Cancer; 2011 Jan; 47(1):65-73. PubMed ID: 20843680
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Trastuzumab for treatment of advanced breast cancers].
    Watanabe T; Shimizu C; Katsumata N; Saijo N
    Nihon Rinsho; 2000 Apr; 58 Suppl():340-4. PubMed ID: 11026016
    [No Abstract]   [Full Text] [Related]  

  • 27. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
    Baselga J; Perez EA; Pienkowski T; Bell R
    Oncologist; 2006; 11 Suppl 1():4-12. PubMed ID: 16971734
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide.
    Feola M; Garrone O; Occelli M; Francini A; Biggi A; Visconti G; Albrile F; Bobbio M; Merlano M
    Int J Cardiol; 2011 Apr; 148(2):194-8. PubMed ID: 19945181
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Trastuzumab-related cardiotoxicity following anthracycline-based adjuvant chemotherapy: how worried should we be?
    Morris PG; Hudis CA
    J Clin Oncol; 2010 Jul; 28(21):3407-10. PubMed ID: 20530269
    [No Abstract]   [Full Text] [Related]  

  • 30. Trastuzumab-induced cardiomyopathy.
    Guglin M; Cutro R; Mishkin JD
    J Card Fail; 2008 Jun; 14(5):437-44. PubMed ID: 18514938
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiotoxicity debated for anthracyclines and trastuzumab in breast cancer.
    Brower V
    J Natl Cancer Inst; 2013 Jun; 105(12):835-6. PubMed ID: 23733910
    [No Abstract]   [Full Text] [Related]  

  • 32. Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast cancer.
    Andreopoulou E; Gaiotti D; Kim E; Volm M; Oratz R; Freedberg R; Downey A; Vogel CL; Chia S; Muggia F
    Clin Breast Cancer; 2007 Aug; 7(9):690-6. PubMed ID: 17919349
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trastuzumab and breast cancer.
    Strasser F; Betticher DC; Suter TM
    N Engl J Med; 2001 Sep; 345(13):996. PubMed ID: 11575296
    [No Abstract]   [Full Text] [Related]  

  • 34. Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase II trial.
    Stickeler E; Klar M; Watermann D; Geibel A; Földi M; Hasenburg A; Gitsch G
    Breast Cancer Res Treat; 2009 Oct; 117(3):591-8. PubMed ID: 19156515
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trastuzumab-related cardiotoxicity in the herceptin adjuvant trial.
    Montemurro F; Redana S; Valabrega G; Martinello R; Aglietta M; Palmiero R
    J Clin Oncol; 2008 Apr; 26(12):2052-3; author reply 2053-4. PubMed ID: 18421060
    [No Abstract]   [Full Text] [Related]  

  • 36. Clinical cardiac tolerability of trastuzumab.
    Perez EA; Rodeheffer R
    J Clin Oncol; 2004 Jan; 22(2):322-9. PubMed ID: 14722042
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiotoxicity associated with trastuzumab treatment of HER2+ breast cancer.
    Fiúza M
    Adv Ther; 2009 Jul; 26 Suppl 1():S9-17. PubMed ID: 19669637
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiac dysfunction in cancer patients receiving paclitaxel.
    Valdés Olmos RA; ten Bokkel Huinink WW; Hoefnagel CA
    Eur J Nucl Med; 1998 Apr; 25(4):446-7. PubMed ID: 9643974
    [No Abstract]   [Full Text] [Related]  

  • 39. High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study.
    Onitilo AA; Engel JM; Stankowski RV; Liang H; Berg RL; Doi SA
    Breast Cancer Res Treat; 2012 Jul; 134(1):291-8. PubMed ID: 22476854
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Trastuzumab before breast surgery? Large trial says yes but does not quell debate.
    Rowan K
    J Natl Cancer Inst; 2009 Apr; 101(7):448-9. PubMed ID: 19318626
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.